We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are ...

The FDA approval is based on late-stage data, which shows that GSK's Blujepa is at least as effective as a leading standard treatment for uncomplicated UTIs.

GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...

The price drop of 23% for Wegovy customers will be available regardless of dose level and insurance status. HealthDay News — The makers of two popular weight-loss drugs — Wegovy and Zepbound — are ...

In 2025, GSK expects to launch five new products/line extensions, including Blenrep, depemokimab (severe asthma and CRSwNP), Nucala for COPD, gepotidacin and pentavalent MenABCWY meningococcal ...

GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below. The stock ...

GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below. The ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other most undervalued ...

A 12-month interim analysis of the AGILE Phase III open-label extension study confirms that twice-yearly depemokimab, an ultra-long-acting anti-IL-5 biologic, maintains a favorable safety and efficacy ...

Overall, 72% of patients were exacerbation free and 96% did not require hospitalization or emergency department visits. GSK has submitted depemokimab for FDA approval.

As retail pharmacies continue to shutter across Northeast Ohio, Cleveland-based MetroHealth is working to fill the gaps. The health system has made it a priority to ensure patients have access to ...